Adaptive TCR, a provider of gene therapies, has changed its name to Adaptive Biotechnologies.
The company said it has changed its name to expand company’s original immune profiling business capabilities and also the translation of select research findings from the lab to the clinic.
Adaptive Biotechnologies CEO and president Chad Robins said replacing TCR with Biotechnologies better represents the full nature and potential of their products and services.
"For example, immunoSEQ now provides B-cell receptor sequencing, and we are developing clinical applications for the diagnosis and prognosis of cancer," Robins said.
ImmunoSEQ utilizes the company’s proprietary immune profiling assay to analyze T cells and B cells which are critical components of the adaptive immune system’s defense against disease with unprecedented depth and specificity.